Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V plus TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer Meeting Abstract

  

Authors:	Dieras, V.; Han, H. S.; Robson, M. E.; Palacova, M.; Marcom, P. K.; Jager, A.; Bondarenko, I.; Citrin, D.; Campone, M.; Telli, M. L.; Domchek, S. M.; Friedlander, M.; Kaufman, B.; Ratajczak, C.; Coates, A.; Bonnet, P.; Qin, Q.; Qian, J.; Giranda, V. L.; Shepherd, S. P.; Puhalla, S.; Isakoff, S. J.
Abstract Title:	Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V plus TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) plus C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer
Meeting Title:	2016 San Antonio Breast Cancer Symposium (SABCS)
Journal Title:	Cancer Research
Volume:	77
Issue:	4 Suppl.
Meeting Dates:	2016 Dec 6-10
Meeting Location:	San Antonio, TX
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2017-02-01
Language:	English
ACCESSION:	WOS:000397999002010
DOI:	10.1158/1538-7445.sabcs16-p4-22-02
PROVIDER:	wos
Notes:	Meeting Abstract: P4-22-02 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/109940